BRPI0711093A2 - composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada - Google Patents

composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada Download PDF

Info

Publication number
BRPI0711093A2
BRPI0711093A2 BRPI0711093-6A BRPI0711093A BRPI0711093A2 BR PI0711093 A2 BRPI0711093 A2 BR PI0711093A2 BR PI0711093 A BRPI0711093 A BR PI0711093A BR PI0711093 A2 BRPI0711093 A2 BR PI0711093A2
Authority
BR
Brazil
Prior art keywords
strain
compound
represent
compound according
formula
Prior art date
Application number
BRPI0711093-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Christine Martin
Ming Zhang
Nigel Coates
William Vousden
Steven Moss
Sabine Gaisser
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609132.6A external-priority patent/GB0609132D0/en
Priority claimed from GB0616637A external-priority patent/GB0616637D0/en
Priority claimed from GBGB0622341.6A external-priority patent/GB0622341D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of BRPI0711093A2 publication Critical patent/BRPI0711093A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0711093-6A 2006-05-09 2007-05-09 composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada BRPI0711093A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0609132.6A GB0609132D0 (en) 2006-05-09 2006-05-09 Novel compounds and methods for their production
GB0609132.6 2006-05-09
GB0616637.5 2006-08-22
GB0616637A GB0616637D0 (en) 2006-08-22 2006-08-22 Novel compounds and methods for their production
GB0622341.6 2006-11-09
GBGB0622341.6A GB0622341D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their preparation
PCT/EP2007/054476 WO2007128829A2 (en) 2006-05-09 2007-05-09 18,21-didesoxymacbecin derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0711093A2 true BRPI0711093A2 (pt) 2011-08-23

Family

ID=38476939

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711093-6A BRPI0711093A2 (pt) 2006-05-09 2007-05-09 composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada

Country Status (9)

Country Link
US (1) US20090253667A1 (enExample)
EP (1) EP1928837A2 (enExample)
JP (1) JP2009536181A (enExample)
KR (1) KR20090005376A (enExample)
AU (1) AU2007247121A1 (enExample)
BR (1) BRPI0711093A2 (enExample)
CA (1) CA2651558A1 (enExample)
MX (1) MX2008014278A (enExample)
WO (1) WO2007128829A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160175A1 (en) * 2006-09-11 2011-06-30 Christine Martin 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
JP2010516282A (ja) 2007-01-26 2010-05-20 コーサン バイオサイエンシーズ， インコーポレイテッド 工学的生合成によるマクロラクタム
CA2679224A1 (en) * 2007-03-01 2008-09-04 Biotica Technology Limited Novel compounds
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN101869138B (zh) * 2010-05-28 2012-05-30 江苏省农业科学院 一种微胶囊发酵剂储存保护液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
CA2628728A1 (en) * 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents

Also Published As

Publication number Publication date
CA2651558A1 (en) 2007-11-15
WO2007128829A3 (en) 2008-01-03
MX2008014278A (es) 2008-11-26
KR20090005376A (ko) 2009-01-13
US20090253667A1 (en) 2009-10-08
EP1928837A2 (en) 2008-06-11
JP2009536181A (ja) 2009-10-08
AU2007247121A1 (en) 2007-11-15
WO2007128829A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
BRPI0711093A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada
US20090209494A1 (en) 21-deoxymacbecin analogues useful as antitumor agents
US20100068203A1 (en) 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies
US20110160175A1 (en) 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer
ES2389740T3 (es) Nuevos compuestos y procedimientos para su producción
US20090117127A1 (en) Novel Compounds and Methods for Their Production
US20090209507A1 (en) 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20110091452A1 (en) 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
US20090298804A1 (en) Novel Compounds and Methods for Their Production
US20100210597A1 (en) C21-Deoxy Ansamycin Derivatives as Antitumor Agents
CN101460465A (zh) 用于癌症治疗的18,21-双脱氧麦克菌素衍生物
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.